Jefferies analyst issued a revised price target for 4D Molecular Therapeutics (NASDAQ:FDMT) stock, lowering it to $40 from the previous $51, while maintaining a Buy rating. Currently trading at $5.48, ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found.

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

The new vaccine is "personalized," meaning it is designed to train the patient's immune system to recognize and eliminate any remaining cells of that person's cancer.